BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

3:45 PM
 | 
Jul 18, 2008
 |  BC Extra  |  Clinical News

Taiho's S-1 misses Phase III endpoint

Taiho said S-1 plus cisplatin missed the primary endpoint of superior overall survival vs. 5-FU plus cisplatin in the open-label, international Phase III FLAGS trial in 1,053 patients with previously untreated,...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >